



GLOBAL MED TECHNOLOGIES[®], INC. PARTNERS WITH BIOMEDICAL SYNERGIES TO OFFER ADVANCED TISSUE TRACKING SOLUTIONS FOR HOSPITALS AND SURGERY CENTERS

Proven human tissue/implant tracking solution now available internationally

Denver, CO – (November 4, 2008) – Global Med Technologies[®], Inc. (“Global Med”) (OTCBB:GLOB), an international e-Health, medical information technology company, and Biomedical Synergies, Inc. (“BSI”), a privately held healthcare consulting and software development company headquartered in Minneapolis, Minnesota, today announced that they have signed an agreement under which Global Med will distribute TRACS4Life™ tissue tracking software. BSI specializes in human tissue/implant tracking management software for the medical industry. Terms of the agreement were not disclosed.

TRACS4Life is a best-of-breed tissue tracking software application for hospitals and surgery centers. Built on Microsoft[®] products, TRACS4Life meets and exceeds the Joint Commission tissue management requirements by streamlining the investigations of worst case scenarios, adverse reactions and product recalls. TRACS4Life uses manufacturers’ barcodes to track and trace human tissue products and to track non-biologic implants from their entrance into a facility through final disposition.

Historically, there has been little standardization and even less coordination of the handling of human tissue products within healthcare facilities. Currently, most facilities utilize a manual tissue-tracking system, which is time consuming at best, inefficient at least, and rife with opportunities for human error. This decentralized tracking method translates into increased times to process a recall and to investigate an adverse event. One hospital recently shared that their time to manually process a recall of only seven tissue products was over two months. This example provides clear insight into how a manual tissue tracking system contributes to substandard patient care, increased facility liability, inefficient clinical operations, lack of regulatory compliance and diminished patient outcomes.

Biomedical Synergies, Inc. was founded by tissue and blood banking experts who offer unparalleled subject matter expertise to augment their software application, a critical differentiation in the marketplace today. One of the founders of BSI, who has contributed much of the intellectual property into the software, is Duke Kasprisin, M.D. Dr. Kasprisin is the past President of the American Association of Tissue Banks (AATB) and was formerly the Chief Medical Officer of the American Red Cross Transplantation Services. BSI’s proven tissue tracking software and business practices assist hospitals with biologic and non-biologic implant product issues, regulatory compliance questions and process inquiries. BSI partners with

facilities to develop compliance infrastructure through Standard Operating Procedures (SOPs), proper organizational structure and software that is designed to increase patient safety, reduce risk and streamline workflows.

Chairman and CEO of Global Med Technologies, Inc., Michael I. Ruxin, M.D., stated, “We are pleased to partner with Biomedical Synergies and their extraordinary team. As a leading provider of blood banking software and services, Global Med has seen first hand the expansion of the blood bank’s responsibility for the administration and oversight of human tissue and cellular therapy products. To meet the needs of our customers worldwide, Global Med will now offer an additional mechanism to decrease the liability for hospitals and accomplish tissue/implant tracking management more effectively and expeditiously.”

Dr. Ruxin continued, “Global Med’s strategy to expand its offerings and grow our revenue base through a mutually beneficial partnership is a win-win for Biomedical Synergies, our customers and the Global Med Family of Companies.”

Global Med will actively promote TRACS4Life to the healthcare marketplace through its direct sales force. This mutually beneficial arrangement will greatly expand the coverage of BSI’s current sales force, allow greater market penetration of TRACS4Life and serve the needs of both Global Med and Biomedical Synergies’ customers and ultimately, and most importantly, help improve patient safety.

Paul Kozloski, President and CEO of Biomedical Synergies, Inc., commented, “This is an exceptional opportunity for Biomedical Synergies to partner with a premier blood banking software company. It offers hospitals the expertise of two naturally synergistic processes and the result directly affects patient outcomes in a highly beneficial manner. Presbyterian/St. Luke’s Medical Center in Denver, Colorado, Christiana Care Health System in 4 sites throughout Delaware, and Indiana Orthopaedic Hospital in Indianapolis, Indiana, are among our valued customers who have implemented TRACS4Life and have immediately realized regulatory compliance, reduced hospital liability and have received a return on their investment through more efficient inventory management. In addition, we are delighted to announce the successful evaluation of TRACS4Life at Brooke Army Medical Center (BAMC) in San Antonio, TX and look forward to a long-standing relationship with them.”

About Biomedical Synergies, Inc.

Biomedical Synergies, Inc. (BSI) is a healthcare consulting and software development firm headquartered in Minneapolis, Minnesota, focused on the human tissue industry and founded by tissue and blood industry experts. Utilizing TRACS4Life, BSI’s patent pending tissue and implant management software, BSI provides products and services to hospitals nationwide pertaining to the management of human tissue, associated surgical implants and manufactured tissue products in their facilities. The combination of BSI’s service offerings and TRACS4Life software allow hospitals to navigate the pitfalls of regulatory compliance, thereby offering a 360° solution to tissue management.

For more information about Biomedical Synergies' products and services, please call 317-842-6502 or visit www.biomedicalsnergies.com or www.tracs4life.com.

Company Contact:
Jeff Winstead, SVP
Business Development
(317) 842-6502

About Global Med Technologies[®], Inc.

Global Med Technologies, Inc. is an international medical software company which develops regulated and non-regulated software products and services for the healthcare industry. As a leading provider of blood and laboratory software applications and services, Global Med's products are deployed in 20 countries and serve over 1,600 transfusion centers, blood banks and laboratories.

Global Med's U.S. division, Wyndgate Technologies[®], provides Vein-to-Vein[®] tracking through its Donor Doc[™], SafeTrace[®], SafeTrace Tx[®] and ElDorado Donor[™] software products. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply.

Global Med's European subsidiary, Inlog, SA, is a leading provider of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally. Inlog's products include EdgeBlood*, EdgeTrack*, EdgeCell, EdgeLab and SAPANET.

Global Med's U.S. division, eDonor[®], provides a web-based donor relationship management system that integrates recruitment, scheduling, retention and fulfillment for national as well as local community blood centers and hospitals. eDonor's products and services are designed to complement Global Med's strong line of international blood management and laboratory information software and service solutions.

Global Med's U.S. subsidiary, PeopleMed[®], Inc., provides cost-effective customized software validation, consulting and compliance solutions to hospitals and donor centers.

For more information about Global Med's products and services, please call 800-996-3428 or visit www.globalmedtech.com, www.peoplemed.com, www.inlog.com, www.eDonor.com, and www.wyndgate.com.

*FDA 510(k) clearance required prior to sales in the U.S.

This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.

Company Contact:
Global Med Technologies, Inc.
Michael I. Ruxin, M.D.
(303) 238-2000
mick@globalmedtech.com

Investor Contact:
portfolio pr
Paul Holm, President
(212) 888-4570
paulmholm@gmail.com